The company adheres to a global deveopment strategy and R&D layout, establishing China-U.S. dual R&D centers with a global perspective. By fully integrating China’s efficiency advantages and North America’s innovation ecosystem, the company rapidly and efficiently conducts breakthrough innovations.

It has built world-class end-to-end innovative R&D capabilities and competitive advantages spanning the fields of ADC, GNC, and ARC therapeutics. This ensures the steady and efficient advancement of the company’s innovative drug R&D, laying a solid foundation for maintaining its industry leadership, continuously iterating innovative technologies, and consistently developing a competitive pipeline of innovative drug products.

Through years of technological innovation and accumulation, the company has established globally leading platforms including the HIRE-ADC Platform (a novel ADC drug R&D platform with global rights and full independent intellectual property), the GNC Platform (a groundbreaking multispecific antibody drug R&D platform), the SEBA Platform (a specificity-enhanced bispecific antibody platform), and the HIRE-ARC Platform (an innovative radiopharmaceutical R&D platform).